Rapid, safe, and efficacious novel therapy for Alzheimer＇s disease
Technology Introduction:
Alzheimer’s disease (AD) is a complex disease with multiple causes. Current drugs are unsafe and ineffective. This technology is a world-leading invention of a novel multi-target therapy for AD. Our team’s trials have found that sodium benzoate can rapidly, safely, and effectively improve the cognition and overall function of patients with early AD through multiple actions, including enhancing NMDA receptor function, regulating sex hormones, increasing endogenous antioxidants, and reducing Aβ.
Industrial Applications:
The dementia market is huge, and new drugs are urgently needed. This technology, leading globally, provides a new approach for Alzheimer’s disease (AD). It is likely to benefit AD patients and to raise Taiwan’s international visibility. This technology has great potential to be approved as a novel treatment for dementia in the future. The product also has the opportunity to be marketed globally, not only increasing employment opportunities but also promoting the development of related new drugs.
Chang Gung Medical Foundation
Chang Gung Medical Foundation is one of Taiwan's largest healthcare organizations, advancing clinical care, biomedical research, medical education, and smart healthcare.
